DE69530389D1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number
DE69530389D1
DE69530389D1 DE69530389T DE69530389T DE69530389D1 DE 69530389 D1 DE69530389 D1 DE 69530389D1 DE 69530389 T DE69530389 T DE 69530389T DE 69530389 T DE69530389 T DE 69530389T DE 69530389 D1 DE69530389 D1 DE 69530389D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions
neuroprotective pharmaceutical
effective
dexanabinol derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69530389T
Other languages
English (en)
Other versions
DE69530389T2 (de
Inventor
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Yoel Kloog
Anat Biegon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Original Assignee
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yissum Research Development Co of Hebrew University of Jerusalem, Pharmos Corp filed Critical Ramot at Tel Aviv University Ltd
Publication of DE69530389D1 publication Critical patent/DE69530389D1/de
Application granted granted Critical
Publication of DE69530389T2 publication Critical patent/DE69530389T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
DE69530389T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen Expired - Fee Related DE69530389T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals
US192886 1994-02-07
PCT/US1995/001470 WO1995020958A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69530389D1 true DE69530389D1 (de) 2003-05-22
DE69530389T2 DE69530389T2 (de) 2004-03-25

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530389T Expired - Fee Related DE69530389T2 (de) 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (1) US5521215A (de)
EP (1) EP0765160B1 (de)
JP (1) JPH09511493A (de)
AT (1) ATE237324T1 (de)
AU (1) AU690221B2 (de)
CA (1) CA2183466A1 (de)
DE (1) DE69530389T2 (de)
IL (1) IL112572A0 (de)
SG (1) SG49625A1 (de)
WO (1) WO1995020958A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
IL128718A0 (en) 1996-09-27 2000-01-31 Guildford Pharmaceuticals Inc Naaldase compositions
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
JP2002501510A (ja) * 1997-05-07 2002-01-15 ユニメッド・ファーマシューティカルズ・インコーポレーテッド ヒトにおける攪乱行動を改善し気分を高揚させる方法
AU727080B2 (en) * 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
EP1223808B1 (de) 1999-10-18 2007-03-07 The University Of Connecticut Für periphäre cannabinoid-rezeptoren selektive liganden
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
HUP0301628A3 (en) * 2000-06-22 2007-05-29 Pharmos Corp Novel non-psychotropic cannabinoids
EP1785417A3 (de) * 2000-06-22 2007-08-01 Pharmos Corporation Neuartige nicht-psychotrope Cannabinoide
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
DE60234246D1 (de) * 2001-04-06 2009-12-17 Univ Illinois Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
AU2002320430A1 (en) * 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
EP1448557A4 (de) * 2001-10-26 2005-02-02 Univ Connecticut Heteroindane: eine neue klasse hochwirksamer cannabimimetischer liganden
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
EP1545502A4 (de) 2002-08-23 2008-12-24 Univ Connecticut Keto-cannabinoide mit therapeutischen indikationen
JP2006502159A (ja) * 2002-09-05 2006-01-19 ファーモス コーポレイション 認知障害を予防するための向精神性のないカンナビノイド
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004050011A2 (en) * 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
WO2007041167A2 (en) * 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
MA40498A (fr) * 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CA3070156A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin
EP3681474A1 (de) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zusammensetzungen und verfahren zur nasalen verabreichung von medikamenten an das gehirn und zur systemischen wirkung
CA3116187A1 (en) 2017-11-29 2019-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
CA3116194A1 (en) 2018-11-04 2020-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ATE237324T1 (de) 2003-05-15
AU690221B2 (en) 1998-04-23
IL112572A0 (en) 1995-05-26
DE69530389T2 (de) 2004-03-25
EP0765160A4 (de) 1997-04-09
US5521215A (en) 1996-05-28
CA2183466A1 (en) 1995-08-10
AU1743395A (en) 1995-08-21
EP0765160A1 (de) 1997-04-02
WO1995020958A1 (en) 1995-08-10
JPH09511493A (ja) 1997-11-18
EP0765160B1 (de) 2003-04-16
SG49625A1 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
ATE237324T1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (de) Neue nicht psychotropische cannabinoide
IL115245A0 (en) Tumor necrosis factor inhibiting pharmaceuticals
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
DE69427704T2 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
SE9604786D0 (sv) New compounds
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
ATE243196T1 (de) Piperidine und pyrrolidine
CA2243404A1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
DK0825197T3 (da) Nye 6-hydroxy- og 6-oxo-androstanderivater, der er aktive i forhold til det cardiovaskulære system, og farmaceutiske præpar
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU2030497A (en) Propynyl or dienyl biaromatic compounds
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
HK1050203A1 (en) Novel fusidic acid derivatives.
EP1785417A3 (de) Neuartige nicht-psychotrope Cannabinoide
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
UA31266A (uk) Лікувальний засіб "дінальгін"
GR980100028A (el) Φαρμακευτικα προιοντα για τοπικη χρηση που περιεχουν φλουκοναζολη σε συγκεντρωσεις μεταξυ 0,2% και 5%

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee